FOLD Amicus Therapeutics, Inc.
USHealthcareAs of 2026-04-27 16:00
Why FOLD matters now
Amicus Therapeutics, Inc. (FOLD) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.49 with +0.00% on the session and $4.55B in market capitalization; recent performance reads 1-month +0.00% and YTD +1.76%.
The latest financial table shown here is Q4 2025, with revenue of $185.2M, net income of $1.7M, and EPS of $0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.7%.
The latest indexable market news headline is "BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $14.50; recent insider activity includes Campbell Bradley L filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
16.33
P/S
7.17
EV/EBITDA
89.56
DCF Value
$-29.29
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.9%
Operating Margin
5.2%
Net Margin
-4.3%
ROE
-12.0%
ROA
-2.9%
ROIC
-645.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $185.2M | $1.7M | $0.01 |
| FY 2025 | $634.2M | $-27.1M | $-0.09 |
| Q3 2025 | $169.1M | $17.3M | $0.06 |
| Q2 2025 | $154.7M | $-24.4M | $-0.08 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$14.50
Target (Median)
$14.50
Target Range
$14.50 - $14.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.48
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.